Problem
• What are the key similarities and differences between the informed consent requirements in the Common Rule and those in Article 29 of the EU Clinical Trials Regulation?
• What is "broad consent" under the Common Rule? How does the option of broad consent facilitate secondary research with identifiable data and biospecimens?